Arecor

Executive Summary

Arecor is a clinical-stage biopharmaceutical company based in Cambridge, UK, specializing in enhanced therapeutics for diabetes and cardiometabolic diseases. Leveraging its proprietary Arestat® technology platform, the company improves the stability, delivery, and performance of existing drugs, particularly insulins and peptides. Arecor pursues both proprietary pipeline development and strategic partnerships with pharmaceutical and medtech firms. The company is currently in Phase 1 clinical development, focusing on next-generation insulin formulations that offer better stability and glucose control. Its technology addresses key limitations of current therapies, potentially enabling more convenient dosing and improved patient outcomes. With a strong intellectual property portfolio and a de-risked approach by reformulating approved drugs, Arecor presents a relatively lower-risk entry into the diabetes market. However, as a private company with limited public information, visibility on funding and clinical timelines remains constrained. The early-stage nature and lack of disclosed pipeline details warrant cautious optimism, but the addressable market and technology validation through partnerships provide a solid foundation for growth.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for lead insulin product60% success
• Q4 2026New partnership or licensing deal with a major pharmaceutical company50% success
• Q2 2026Preclinical proof-of-concept data for next-generation peptide formulation70% success